News
Tb-161: Novel Radionuclide to be Tested
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with
CarGurus Makes Grant to NETRF
The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a
New Grant Explores Novel Drug Delivery System
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama
Navigating Neuroendocrine Tumors: New NCCN Guidelines for Patients
The National Comprehensive Cancer Network® (NCCN®) has published a brand new NCCN Guidelines for Patients focused on neuroendocrine tumor (NET). These new guidelines offer up-to-date
Brendan P. Foley Jr. Joins NETRF Board of Directors
We are proud to welcome Brendan P. Foley, Jr. as the newest member of the NET Research Foundation Board of Directors. Brendan has been elected
Spark Hope: A $10 Million Campaign for NET Research
NETRF has launched a $10 million fundraising campaign, the largest of its kind in our history. Every gift we receive will be MATCHED, doubling our
Leaving Neuroendocrine Cancer Behind
NET Survivor Finds Hope and Inspiration That’s it—my number is up, Dave McCoy thought when he learned he had neuroendocrine cancer in 2008. A cancer, he
Immunotherapy Update: What We’ve Learned
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
Small community experiences big impact from NETs
In between Sebago Lake and Casco Bay, there’s a Maine community where many people know about NET cancer and can even name someone who has
The passing of Aretha Franklin, Queen of Soul
We are saddened to hear of the passing of Aretha Franklin, the Queen of Soul, who died of a pancreatic neuroendocrine tumor (pNET). She was